Skip to main content

Table 3 Bleeding complications in patients with cancer treated with certoparin or UFH

From: Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY

Pts with cancer at admission

Certoparin

UFH

OR (95%CI)

p-value*

 

n/avail.

%

n/avail.

%

  

Patients with cancer at admission

      

   with major bleeding

1/133

0.75

1/141

0.71

1.06 (0.07-17.13)

0.9669

   with minor bleeding

1/133

0.75

8/141

5.67

0.13 (0.02-1.02)

0.0523

  1. Legend: Pts, patients; SD, UFH, unfractionated heparin; OR, odds ratio; CI, confidence interval, * two-sided p-value for null-hypothesis: difference = 0 or odds ratio = 1.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us